Interpace Diagnostics

Interpace Biosciences, Inc. engages in the development and sale of diagnostic clinical and pharma services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test, ThyGenX, an expanded oncogenic mutation panel that helps identify malignant thyroid nodules, ThyraMIR, which assesses thyroid nodules for risk of malignancy, and RespriDx, a genomic test that helps physicians differentiate metastatic or recurrent lung cancer. The company was founded by John P. Dugan in 1986 and is headquartered in Parsippany, NJ.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

 Podium Presentation Accepted for the American Society of Cytopathology (ASC) Annual Meeting

Interpace Announces Acceptance of Seminal Clinical Validation Study for Thyroid Assays

Interpace Biosciences, Inc. (IDXG) CEO Jack Stover on Q1 2020 Results - Earnings Call Transcript

First Quarter Net Revenue Improved Over 53% to $9.2 Million

Interpace Biosciences Announces First Quarter 2020 Financial and Business Results

In-Network Access for More Than 3 Million Members

Interpace Biosciences Announces Contract with Lab Benefits Management Firm

Conference Call and Webcast Wednesday April 22, 2020 5:00 pm ET

Interpace Biosciences Announces Full Year and Fourth Quarter 2019 Financial and Business Results and Preliminary Q1-2020 Results

Interpace Biosciences (NASDAQ: IDXG) provides complex molecular analysis for the early diagnosis and treatment of cancer.

Interpace Biosciences CEO Jack Stover On Diagnostics Business: 'Much Of The Growth Opportunity Is Around Awareness'

Parsippany, NJ, March  11, 2020  (GLOBE NEWSWIRE) -- Interpace Diagnostics, a subsidiary of Interpace Biosciences (NASDAQ: IDXG) announced today that it has entered into a contract with Blue Cross Blue Shield of Massachusetts. While terms of this Agreement are not disclosed, Interpace is an in-network lab with Blue Cross Blue Shield of Massachusetts for all product lines.

Interpace Diagnostics Issues Update Regarding Announced Contract with BCBS of Massachusetts

Interpace Diagnostics Announces Contract with BCBS of Massachusetts

Parsippany, NJ, March  02, 2020  (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced acceptance of the first manuscript reporting the clinical performance of the company’s ThyGeNEXT® and ThyraMIR® tests in the Journal of the American Society of Cytopathology. The article, entitled “Clinical performance of multiplatform mutation panel and microRNA risk classifier in indeterminate thyroid nodules”, will be published online in the coming weeks.

Interpace Biosciences Announces Acceptance of first paper Demonstrating Clinical Performance of ThyGeNEXT with ThyraMIR

Parsippany, NJ, Feb.  11, 2020  (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that the Center for Medicare and Medicaid Services (CMS) has modified the reimbursement for Interpace Diagnostics’ ThyraMIR® miRNA classifier for evaluating indeterminate thyroid nodules retroactively to January 1, 2020. This determination increases the Medicare reimbursement for ThyraMIR® from approximately $1800 to $3000 reflecting a re-evaluation of the technical and clinical performance of the test relative to other molecular tests in the market and their respective prices. Today, approximately 30% of the Company’s ThyraMIR® volume is attributable to Medicare eligible patients.

Interpace Biosciences Announces Another Pricing improvement for its Thyroid Assay

PARSIPPANY, NJ, Jan.  30, 2020  (GLOBE NEWSWIRE) -- Interpace Biosciences , Inc. (NASDAQ: IDXG) (“Interpace”) a leader in enabling personalized medicine, is pleased to announce today that Ron Rocca, President & CEO of Exagen, Inc. (NASDAQ: XGN) has been appointed to the Interpace Board of Directors. Ron has significant experience as a senior executive at companies which develop and market high value, proprietary tests. In addition to serving as CEO of Exagen since 2011, Mr. Rocca served as VP of Sales & Marketing and General Manager of Prometheus Laboratories from 2005 to 2011.

Interpace Biosciences Announces Addition to Board of Directors and Changes in Leadership

Compugen

Glu Mobile

GameStop

Groupon

Meet Group

OrganiGram Holdings Inc.

RTI Surgical

Synlogic

Zynga

With stocks at all time highs and after the Dow rose more than 22% and the S&P 500 rose over 28% in 2019, many investors have yet to make many changes in the portfolios for what could be another solid 2020.

10 Stocks Trading Under $10 With Massive Upside Potential in 2020

Underappreciated Drivers, Bargain Valuation & Cash Infusion Set Interpace Up For Substantial Upside

Underappreciated Drivers, Bargain Valuation, And Cash Infusion Set Interpace Up For Substantial Upside

Reverse Stock Split Planned Concurrent with Closing

Interpace Biosciences Enters into Agreement for $20 Million Investment from 1315 Capital and Ampersand Capital Partners

Parsippany, NJ, Jan.  06, 2020  (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG), a leader in enabling personalized medicine, today announced that the Company’s wholly-owned subsidiary, Interpace Diagnostics has entered into a collaborative study aimed at exploring the potential use of BarreGEN® in patients undergoing radiofrequency ablation (RFA). RFA is typically known as a cancer preventative therapy that either delays or arrests the progression of Barrett’s Esophagus to esophageal cancer. Evidence to date suggests that BarreGEN® may identify non-dysplastic Barrett’s Esophagus patients in need of ablation, making targeted ablation a potentially cost-effective treatment option. This new collaborative study performed in partnership with the University of North Carolina Division of Gastroenterology under the direction of Nick Shaheen, MD MPH, using the BarreGEN® assay developed by Interpace aims to target the potential for molecular changes to predict resistance or relapse following RFA.

Interpace Biosciences Announces Collaborative Study with University of North Carolina to Assess the Use BarreGEN® after Ablation of Dysplastic Barrett’s Esophagus

Parsippany, NJ, Dec.  17, 2019  (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that its Medicare Administrative Contractor (MAC) has issued a new draft local coverage determination (LCD) for the Company’s ThyGeNEXT® test, representing an increase of approximately $2,400 per assay over previous reimbursement coverage. This increase in reimbursement rates reflects the expansion of the ThyGeNEXT® panel to aid in identifying the appropriate patients for surgery. In 2018, Interpace processed approximately 12,500 ThyGeNEXT® tests.

Interpace Biosciences Announces New Draft LCD and Reimbursement for Its Proprietary Thyroid Assay, ThyGeNEXT®

Further Strengthens Business Development Team with Key Hire

Interpace Biosciences Expands Strategic Partnership Activities with Genecast Biotechnology in China

PARSIPPANY, NJ, Dec.  02, 2019  (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (IDXG) announced today that it is launching its new corporate website, “Interpace.com”. Now both the Diagnostics and Pharma Solutions businesses of Interpace are represented together on one easy to navigate website. The site provides information on the offerings of both divisions including diagnostic and tailored laboratory services testing, patient support, physician education, clinical trial data management, project management, and bioinformatics. The combined businesses represent a broad spectrum of products and services offered to both the physician and pharmaceutical company constituencies and demonstrate how Interpace Biosciences can both help resolve diagnostic uncertainty and empower better medicine

Interpace Biosciences Launches New Corporate Website

Interpace Diagnostics Group, Inc. (IDXG) CEO Jack Stover on Q3 2019 Results - Earnings Call Transcript

﻿Third Quarter Revenue Grew 34% Over the Prior Year’s Quarter and 25% Year to Date

Interpace Diagnostics Changes Name to Interpace Biosciences; Announces Plans for Next Phase of Growth and Third Quarter 2019 Financial Results

Clinical Data Highlights the Utility of ThyGeNEXT® and ThyraMIR®

Interpace Diagnostics Announces Publication of New Data on Thyroid Test Utility

PARSIPPANY, NJ, Oct.  29, 2019  (GLOBE NEWSWIRE) -- Interpace (IDXG) announced today that it will be presenting new data on the performance of its molecular thyroid products at the upcoming 89th Annual Meeting of the American Thyroid Association (ATA), being held October 30th to November 3rd, 2019 in Chicago, IL. The ATA meeting is one of the largest gatherings of endocrinologists, ENT’s, surgeons and other providers who focus on the diagnosis and treatment of thyroid cancer.

Interpace to Present Data at the ATA Annual Meeting

Interpace hosts 2nd Annual Fellow Programs

Interpace to Present at the American College of Gastroenterology Conference

PARSIPPANY, NJ, Oct.  17, 2019  (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (IDXG) announced today that it has closed on a $13 million Convertible Preferred Stock investment by Ampersand Capital Partners (Ampersand). This investment constitutes the second tranche of the overall $27 million Convertible Preferred Stock financing provided by Ampersand to Interpace in connection with the Company’s July 15, 2019 acquisition of the BioPharma Business of Cancer Genetics, Inc. (CGIX). The condition surrounding the second tranche financing was approved by Interpace shareholders which was obtained at the Annual Shareholder Meeting on October 10, 2019. Approximately $6 million of the second tranche financing is being used to pay down a note due to Cancer Genetics, subject to related contractual adjustments, in connection with the acquisition.

News for Interpace Diagnostics Stock (IDXG)